CLINICAL TRIALS PROFILE FOR DEXAMETHASONE

505(b)(2) Clinical Trials for DEXAMETHASONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Rogel Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00135187 ↗	Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma	Completed	University of Michigan Cancer Center	N/A	2004-07-01	Patients are being asked to take part in this research study because they have multiple myeloma which has relapsed after (come back), or is refractory to (unaffected by), initial therapy. For patients who have relapsed or are refractory to therapy, there is no agreed upon standard treatment. Treatment options include chemotherapy and, for some patients, bone marrow transplants. None of the available treatments are curative and investigators are continually looking for more effective treatments. This study involves treatment with a new combination of standard drugs: VELCADE, Doxil, and Dexamethasone. Preliminary results from a study using a combination of VELCADE with Doxil showed high response rates (disease reduction). Two other studies showed that an addition of Dexamethasone to VELCADE in patients not responding to VELCADE alone improved response rate. The proposed combination of all three drugs may improve efficacy and response. VELCADE is approved by the Food and Drug Administration (FDA) for use in multiple myeloma. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is approved for use in multiple myeloma. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with VELCADE, Doxil and Dexamethasone is an effective treatment, and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00135187 ↗	Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma	Completed	University of Michigan Rogel Cancer Center	N/A	2004-07-01	Patients are being asked to take part in this research study because they have multiple myeloma which has relapsed after (come back), or is refractory to (unaffected by), initial therapy. For patients who have relapsed or are refractory to therapy, there is no agreed upon standard treatment. Treatment options include chemotherapy and, for some patients, bone marrow transplants. None of the available treatments are curative and investigators are continually looking for more effective treatments. This study involves treatment with a new combination of standard drugs: VELCADE, Doxil, and Dexamethasone. Preliminary results from a study using a combination of VELCADE with Doxil showed high response rates (disease reduction). Two other studies showed that an addition of Dexamethasone to VELCADE in patients not responding to VELCADE alone improved response rate. The proposed combination of all three drugs may improve efficacy and response. VELCADE is approved by the Food and Drug Administration (FDA) for use in multiple myeloma. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is approved for use in multiple myeloma. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with VELCADE, Doxil and Dexamethasone is an effective treatment, and also to determine the side effects that occur when this combination treatment is given.

All Clinical Trials for DEXAMETHASONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000563 ↗	Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1976-06-01	To determine the effect of corticosteroids, administered 24 to 48 hours before parturition, on the incidence of neonatal respiratory distress syndrome (RDS) and to determine whether the therapy has any adverse short- or long-term (up to 36 months) effects on the infant. Secondarily, to determine whether the therapy has any adverse short-term effects on the mother and to determine whether morbidity rates for neonatal respiratory distress syndrome as well as total and cause-specific infant mortality rates differ between mothers who received antenatal steroids and those who received conventional medical care.
NCT00000621 ↗	Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1999-09-01	To conduct feasibility studies on the use of retinoids in the treatment of emphysema. Specific objectives are to identify optimal patient populations, retinoids, doses, dosing schedules, routes of administration, and outcome measures preparatory to conducting a larger, controlled, clinical trial on the efficacy of retinoid therapy in the management of emphysema.
NCT00000658 ↗	A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma	Completed	Schering-Plough	Phase 3	1969-12-31	To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL. While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been disappointing. Treatment is frequently complicated by the occurrence of multiple opportunistic infections, as well as the presence of poor bone marrow reserve, making the administration of standard doses of chemotherapy difficult. A recent study was completed using a low-dose modification of the standard mBACOD (cyclophosphamide, doxorubicin, vincristine, bleomycin, dexamethasone, methotrexate ) treatment. A 46 percent response rate was observed in patients treated with this combination of chemotherapeutic agents, with a number of durable remissions and reduced toxicity when compared to previous experience with more standard treatments. A subsequent study showed similar effectiveness using a lower dose of methotrexate administered on day 15. It is hoped that the use of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function and allow for administration of a higher dose of chemotherapy.
NCT00000658 ↗	A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL. While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been disappointing. Treatment is frequently complicated by the occurrence of multiple opportunistic infections, as well as the presence of poor bone marrow reserve, making the administration of standard doses of chemotherapy difficult. A recent study was completed using a low-dose modification of the standard mBACOD (cyclophosphamide, doxorubicin, vincristine, bleomycin, dexamethasone, methotrexate ) treatment. A 46 percent response rate was observed in patients treated with this combination of chemotherapeutic agents, with a number of durable remissions and reduced toxicity when compared to previous experience with more standard treatments. A subsequent study showed similar effectiveness using a lower dose of methotrexate administered on day 15. It is hoped that the use of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function and allow for administration of a higher dose of chemotherapy.

Clinical Trial Conditions for DEXAMETHASONE

Condition Name

Condition Name for DEXAMETHASONE
Intervention	Trials
Multiple Myeloma	676
Leukemia	95
Lymphoma	90
Postoperative Pain	85

Condition MeSH

Condition MeSH for DEXAMETHASONE
Intervention	Trials
Multiple Myeloma	986
Neoplasms, Plasma Cell	884
Lymphoma	292
Leukemia	271

Clinical Trial Locations for DEXAMETHASONE

Trials by Country

Trials by Country for DEXAMETHASONE
Location	Trials
Canada	841
Russian Federation	96
India	95
Switzerland	95
Sweden	94

Trials by US State

Trials by US State for DEXAMETHASONE
Location	Trials
New York	478
Texas	473
California	454
Massachusetts	341
Florida	325

Clinical Trial Progress for DEXAMETHASONE

Clinical Trial Phase

Clinical Trial Phase for DEXAMETHASONE
Clinical Trial Phase	Trials
PHASE4	92
PHASE3	61
PHASE2	114

Clinical Trial Status

Clinical Trial Status for DEXAMETHASONE
Clinical Trial Phase	Trials
COMPLETED	1465
Recruiting	849
Not yet recruiting	336

Clinical Trial Sponsors for DEXAMETHASONE

Sponsor Name

Sponsor Name for DEXAMETHASONE
Sponsor	Trials
National Cancer Institute (NCI)	334
M.D. Anderson Cancer Center	138
Celgene Corporation	124

Sponsor Type

Sponsor Type for DEXAMETHASONE
Sponsor	Trials
Other	4631
Industry	1696
NIH	404

Dexamethasone Clinical Trials Update, Market Analysis, and Exclusivity/Competition Outlook (2026)

Last updated: May 20, 2026

Dexamethasone is a long-established systemic corticosteroid with broad, multi-indication use and widely distributed generic competition. Current market and “clinical trials” dynamics are dominated by (1) new delivery systems and fixed-dose combinations, (2) expanded label indications in specific disease settings, and (3) oncology- and immunology-adjacent controlled-release or topical/ophthalmic formulations. On the global level, pricing and volume are constrained primarily by generics and off-patent status in most jurisdictions.

Because dexamethasone is off-patent in essentially all major markets, the realistic R&D and licensing focus is formulation IP, method-of-use IP for specific dosing regimens, and life-cycle management for specialized delivery formats (ophthalmic, intravitreal-like approaches where applicable, inhaled/topical, and combination products). The competitive base includes multinational sterile and non-sterile manufacturers with extensive ANDA and local-market portfolios.

What is the current clinical trials landscape for dexamethasone (and what’s actually driving new studies)?

The clinical trial surface for dexamethasone is large but fragmented. Search-term relevant trial updates tend to cluster into the following intent areas:

Which disease areas dominate dexamethasone interventional trials?

• Respiratory viral and inflammatory syndromes: trials evaluating steroid timing and dosing in viral pneumonias and hyperinflammation phenotypes.
• Oncology supportive care: antiemetic or anti-inflammatory regimens, often as part of multi-drug protocols where dexamethasone dosing is standardized by treatment regimens (hematologic and solid tumors).
• Immunology: autoimmune flare reduction and steroid-sparing strategies when combined with other agents.
• Ophthalmology: posterior and anterior segment inflammatory indications using specific formulation constraints (dose frequency, preservative system, viscosity).
• ENT and dermatology (topical): anti-inflammatory indications with device/formulation-specific endpoints.

Are trials using dexamethasone for COVID-19 still active?

Most COVID-era dexamethasone efforts moved to completed outcomes or follow-on observational cohorts. Any remaining interventional activity is generally tied to subpopulations, dosing comparisons, or combination strategies in complex care pathways rather than standalone “historic” claims.

What endpoints are most common in recent dexamethasone studies?

• Hospital course metrics (time to clinical improvement, oxygen requirement changes)
• Mortality or intensive care admission in acute inflammatory conditions
• Symptom scores and inflammatory markers in chronic inflammatory indications
• Visual acuity and anterior chamber inflammation scores in ophthalmic studies
• Treatment completion and adverse event profiles in oncology supportive-care protocols

Practical read-through for R&D: Where new trials exist, they usually aim to tighten regimen-specific label language, support a new formulation/delivery format, or improve tolerability through excipient changes or dosing frequency.

What patents protect dexamethasone today, and what is the “IP that still matters”?

Dexamethasone as a chemical entity is long off-patent. The active IP relevance in the market comes from:

How many patents cover dexamethasone formulations, and what types are most common?

• Formulation and process patents: sterile manufacturing processes, controlled release technologies, stability enhancements, and preservative system formulations for ophthalmic or topical products.
• Device-adjacent patents: combination packs, delivery systems (inhaled/topical applicators), or integrated administration methods.
• Method-of-use patents: specific dosing schedules or combinations in defined clinical contexts.
• Polymorph/solid-state patents: less common for steroids than for newer small molecules, but can appear in combination products or specialty formulations.

How strong is the patent estate for dexamethasone?

In most large markets, enforceable exclusivity for the molecule itself is not a meaningful barrier. For litigation and licensing, only formulation and regimen-specific claims are typically actionable. The practical effect is that generics can launch for the API-based product, while brand protection persists for specific dosage forms or proprietary regimens that map to additional clinical differentiation.

When does dexamethasone lose exclusivity in major markets?

What is the status of dexamethasone molecule exclusivity?

• Molecule-level regulatory exclusivity: effectively expired worldwide due to long commercialization.
• Product/dosage-form exclusivity: only persists for any newer branded or reformulated presentations that secured protection via formulations, processes, or method-of-use claims.

What timing still matters for “exclusivity-like” barriers?

• Orange Book-listed patents for particular products and strengths (if any) can still create barriers for those specific NDA holders.
• Country-specific data protections can matter for newly approved combinations or reformulated versions, even if dexamethasone API is generic.

Net effect: market entry risk for dexamethasone API is low for generic manufacturers. Market entry risk for a specific branded presentation depends on whether there are still listed patents covering that presentation and whether any Paragraph IV challenges are feasible.

What is the Orange Book status of dexamethasone products, and which patents are typically listed?

Orange Book status depends on the specific branded or innovator NDA product, not the API as a whole.

What is usually listed for dexamethasone in Orange Book records?

• Formulation patents (composition and formulation)
• Use patents (methods of treatment)
• Manufacturing/process patents for certain presentations
• Device/combination-related patents for specific products

Which strengths and dosage forms are most relevant for patent listing?

• Ophthalmic suspensions and drops at specific strengths
• Injectable presentations (where formulation/process claims can be listed)
• Fixed-dose combinations (less common for dexamethasone, more common for branded steroid regimens in specific markets)

Practical read-through: The most relevant barriers for competitors are product-specific patents, not dexamethasone itself.

How do dexamethasone clinical-trial findings translate into market adoption and payer behavior?

What determines whether trial results change prescribing patterns?

• Clinically meaningful endpoints (reduced time to improvement, reduced progression, improved safety)
• Integration into existing care pathways (e.g., dosing compatibility with standard oncology regimens)
• Availability of a formulation that improves tolerability or reduces administration burden
• Local reimbursement and guideline inclusion

What is the likely market outcome for positive trials?

• If trials support a broader label for dexamethasone as part of a regimen, prescribing may increase but price erosion remains driven by generics.
• If trials support a novel formulation (improved stability, reduced dosing frequency, improved ocular tolerability), market share can shift toward that presentation’s patent-protected commercial model.

Market analysis: Who sells dexamethasone, where is volume concentrated, and how do prices behave?

Revenue and volume dynamics

• Global dexamethasone demand is driven by hospital use (injectable and systemic) and chronic care settings (topical and ocular).
• Price competition is intense because dexamethasone is widely genericized.
• Growth typically comes from (1) utilization expansion by new indications, (2) substitution into standard of care in additional diseases, and (3) incremental share capture by specialty formulations rather than API-driven premium pricing.

Market structure by supply capability

• Sterile injectables: dominated by established sterile manufacturing networks and broad generic portfolios.
• Ophthalmics: competitive among multiple manufacturers with differences in excipients, preservative systems, and suspension characteristics.
• Topical/ENT: many suppliers with local distribution advantages.

Competitive landscape

• Generic competitors compete largely on price, availability, and supply reliability.
• Differentiation appears in formulation stability, presentation convenience, and sometimes local regulatory approvals.

Clinical trials update by product type: systemic vs ophthalmic vs topical

Systemic (oral and injectable)

• Trial activity is generally regimen-specific: dosing schedule comparisons, timing windows, and safety in specific patient phenotypes.
• Market adoption tracks hospital formulary decisions and guideline updates more than standalone API approvals.

Ophthalmic

• Trials target inflammation control, steroid responder considerations, dosing frequency, and safety outcomes such as IOP elevation risk.
• Market differentiation tends to be stronger if a formulation enables fewer administrations or better tolerability.

Topical/dermatologic/ENT

• Trial endpoints are symptom scales, inflammation resolution, and adherence-related outcomes tied to vehicle/formulation.
• Commercial performance tends to correlate with product labeling specificity and inclusion in practice guidelines.

Biosimilar risk and biologics competition: does it apply to dexamethasone?

Dexamethasone is not a biologic. Biosimilar risk is not a relevant concept for dexamethasone. Competitive pressure instead comes from:

• Other corticosteroids (prednisone, methylprednisolone, budesonide, triamcinolone)
• Targeted anti-inflammatory and immunomodulatory therapies that can reduce steroid dependence
• Fixed regimens where dexamethasone remains a standard component due to cost and evidence

What generic entry risks exist for dexamethasone?

For dexamethasone API-based products

• Generic entry risk is low because the molecule is off-patent and manufacturing know-how is widely distributed.
• The main gating items are current product-specific exclusivity (if any), supply chain, and regulatory compliance.

For specific branded presentations

• Risks concentrate on whether there are still listed patents tied to that presentation.
• If patents exist, generic entry can still occur via:
  • Patent expiration timing (if listed patents are enforceable)
  • Settlement-driven delays
  • Paragraph IV challenges (where practicable)

What patent litigation affects dexamethasone?

Patent litigation for dexamethasone is typically not about blocking access to the API. It is usually about:

• Whether a competitor infringes formulation or use patents tied to a specific product and strength
• Whether generic label or formulation design design-arounds are sufficient
• Whether settlement agreements impose delayed entry tied to specific products

How does dexamethasone compare with other corticosteroids (market and clinical)?

Substitution pattern

• Clinicians choose among corticosteroids based on potency, onset/duration, route of administration, and steroid-specific safety management.
• Dexamethasone often wins in contexts requiring high potency or specific dosing practicality, especially where strong evidence exists for particular regimen integration.

Commercial comparison

• Dexamethasone competes with multiple generics in the same therapeutic classes.
• Price is a key determinant, so market share changes are typically modest unless a new formulation or label expansion provides a clear advantage.

Forward projections: what to expect for dexamethasone through 2027–2030?

Base case market outcome (systemic and generic core)

• Continued volume with erosion in unit pricing.
• Moderate growth tied to utilization expansion in supportive care and inflammatory indications.
• Limited opportunity for sustained premium pricing at the API level.

Growth pockets (likely areas of incremental share)

• Specialty ophthalmic presentations where dosing convenience or tolerability can be differentiated
• Combination products if new approvals create short-lived data protection or if formulation patents remain enforceable
• Niche indications where method-of-use language increases uptake and where formulation constraints matter clinically

Projection table (directional)

Segment	2026 outlook	2027-2030 outlook	Key driver
Systemic injectables	Stable demand	Flat to low growth	Hospital utilization, generics pricing
Systemic oral	Stable demand	Flat to low growth	Standard-of-care integration
Ophthalmic	Moderate share competition	Low growth	Formulation differentiation, local label specifics
Topical/ENT	Competitive	Low growth	Guideline-driven seasonal/utilization patterns
New combinations	Limited	Conditional	Regulatory approvals and product lifecycle IP

Key deal and licensing implications for partners

What is licensable in dexamethasone’s “real” market?

• Formulation IP for specific dosage forms and stability/process improvements
• Method-of-use claims tied to defined dosing schedules or combinations
• Proprietary packaging, delivery devices, and patient adherence improvements

Where are the highest-value partnering opportunities?

• Specialty ophthalmic and formulation-driven differentiation
• Controlled-release or stability-optimized sterile products where manufacturing process yields cost or quality advantages
• Region-specific regulatory strategy for combinations or reformulations

Key Takeaways

• Dexamethasone is off-patent at the molecule level; current “exclusive value” comes from formulation, process, and product-specific method-of-use IP for particular dosage forms.
• Clinical trial updates tend to be regimen- and formulation-specific rather than novel API discovery.
• Market growth is constrained by generic competition; meaningful share shifts occur when a new presentation improves tolerability, dosing frequency, or fits guideline-driven regimen structures.
• Licensing and litigation activity, where present, is product-specific (Orange Book listed patents for specific branded presentations) rather than API-level exclusivity.

FAQs

1) Which dexamethasone dosage forms have the most product-specific patent barriers?
Ophthalmic and certain sterile injectable presentations are the most likely to have formulation/process and use-related patent listings tied to specific NDA products.

2) Can a generic manufacturer launch dexamethasone immediately in the US?
Generic launch feasibility depends on whether a particular branded presentation has still-enforceable Orange Book-listed patents; the API is not a persistent barrier.

3) What therapeutic areas still generate new dexamethasone clinical evidence?
Acute inflammatory respiratory syndromes, oncology supportive care regimens, immunology strategy trials, and ophthalmic inflammation control.

4) Does dexamethasone face biosimilar competition?
No. It is a small-molecule corticosteroid, not a biologic; competition comes from other steroids and targeted therapies.

5) What are the most defensible R&D paths for dexamethasone going forward?
Formulation and process improvements for stability, tolerability, and dosing convenience, plus regimen-specific method-of-use claims tied to defined patient populations.

References

No sources were cited because no specific dexamethasone product, jurisdictional Orange Book listings, trial registry IDs, or company/filing data were provided in the prompt.